X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DIVIS LABORATORIES PLETHICO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -1.1 29.0 - View Chart
P/BV x 0.0 5.0 0.3% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 PLETHICO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-17
PLETHICO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3951,222 32.3%   
Low Rs31784 4.0%   
Sales per share (Unadj.) Rs604.4153.1 394.8%  
Earnings per share (Unadj.) Rs32.539.9 81.3%  
Cash flow per share (Unadj.) Rs51.344.6 115.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs473.6201.8 234.7%  
Shares outstanding (eoy) m34.08265.47 12.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.46.6 5.4%   
Avg P/E ratio x6.625.1 26.1%  
P/CF ratio (eoy) x4.222.5 18.5%  
Price / Book Value ratio x0.55.0 9.1%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m7,262266,266 2.7%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m1,5964,687 34.0%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m20,59840,643 50.7%  
Other income Rs m386749 51.6%   
Total revenues Rs m20,98441,392 50.7%   
Gross profit Rs m2,81814,460 19.5%  
Depreciation Rs m6421,233 52.1%   
Interest Rs m1,59323 7,049.6%   
Profit before tax Rs m96913,953 6.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1383,349 -4.1%   
Profit after tax Rs m1,10710,604 10.4%  
Gross profit margin %13.735.6 38.4%  
Effective tax rate %-14.324.0 -59.5%   
Net profit margin %5.426.1 20.6%  
BALANCE SHEET DATA
Current assets Rs m18,87740,105 47.1%   
Current liabilities Rs m11,8966,595 180.4%   
Net working cap to sales %33.982.5 41.1%  
Current ratio x1.66.1 26.1%  
Inventory Days Days36119 30.3%  
Debtors Days Days19881 245.2%  
Net fixed assets Rs m9,86119,995 49.3%   
Share capital Rs m341531 64.2%   
"Free" reserves Rs m12,33153,043 23.2%   
Net worth Rs m16,13953,574 30.1%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14661,585 53.8%  
Interest coverage x1.6618.4 0.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.7 94.2%   
Return on assets %8.117.3 47.2%  
Return on equity %6.919.8 34.7%  
Return on capital %12.326.1 47.1%  
Exports to sales %21.40-   
Imports to sales %15.225.2 60.3%   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,13610,259 30.6%   
Fx inflow Rs m4,40235,384 12.4%   
Fx outflow Rs m3,18410,399 30.6%   
Net fx Rs m1,21924,985 4.9%   
CASH FLOW
From Operations Rs m2,43711,493 21.2%  
From Investments Rs m-6,265-11,372 55.1%  
From Financial Activity Rs m2,490-93 -2,674.7%  
Net Cashflow Rs m-1,33728 -4,708.3%  

Share Holding

Indian Promoters % 82.7 52.0 159.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.8 36.4%  
FIIs % 5.5 19.0 28.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.2 43.6%  
Shareholders   10,665 31,796 33.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS